Company / Return on Equity (ROE)
AIM ImmunoTech Inc. Return on Equity (ROE) History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-283.0%
FY2024
5-year range
-283.0% / -23.5%
FY2020-FY2024
Trend
-459.8%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
AIM ImmunoTech Inc. reports negative total equity of -283.0% in FY2024. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-283.0% in FY2024 with a 5-year CAGR of -213.0%.
Declined from -33.6% to -283.0% over the past 2 years.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -259.5pp
- 5-Year Change
- -213.0pp
- 10-Year Change
- -
Key checks
Key Insights
- AIM ImmunoTech Inc.'s return on equity (roe) has declined for 3 consecutive years.
- In FY2024, return on equity (roe) decreased 459.8% year-over-year.
- Peak return on equity (roe) was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score -71.45 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | -283.0% | -459.8% |
| FY2023 | -50.5% | -50.3% |
| FY2022 | -33.6% | -43.2% |
| FY2021 | -23.5% | +0.0% |
| FY2020 | -23.5% | +66.4% |
| FY2019 | -70.0% | +60.3% |
| FY2018 | -176.1% | -79.2% |
| FY2017 | -98.3% | -103.0% |
| FY2016 | -48.4% | +35.2% |
As of FY2024 · SEC 10-K · Updated Jun 24, 2026